Correlation between XCIPs and clinicohematologic features in female patients with essential thrombocythemia
| Feature . | Clonal XCIP, n = 54 . | Polyclonal XCIP, n = 15 . | P . |
|---|---|---|---|
| Age, y | 57.7 ± 19.9 | 45.3 ± 15.5 | .029 |
| Hematocrit, % | 36.2 ± 5.4 | 37.0 ± 3.2 | .457 |
| WBC count, × 109/L | 15.3 ± 7.7 | 13.3 ± 9.3 | .403 |
| Platelet count, × 109/L | 1309.1 ± 424.8 | 1176.7 ± 276.7 | .259 |
| LAP score | 136.1 ± 67.9 | 131.9 ± 53.5 | .824 |
| Follow-up, mo | 53.0 ± 36.4 | 49.0 ± 23.8 | .614 |
| Splenomegaly, no. patients | 14 | 2 | .492 |
| Myelofibrosis, no. patients | 19 | 6 | 1.000 |
| Feature . | Clonal XCIP, n = 54 . | Polyclonal XCIP, n = 15 . | P . |
|---|---|---|---|
| Age, y | 57.7 ± 19.9 | 45.3 ± 15.5 | .029 |
| Hematocrit, % | 36.2 ± 5.4 | 37.0 ± 3.2 | .457 |
| WBC count, × 109/L | 15.3 ± 7.7 | 13.3 ± 9.3 | .403 |
| Platelet count, × 109/L | 1309.1 ± 424.8 | 1176.7 ± 276.7 | .259 |
| LAP score | 136.1 ± 67.9 | 131.9 ± 53.5 | .824 |
| Follow-up, mo | 53.0 ± 36.4 | 49.0 ± 23.8 | .614 |
| Splenomegaly, no. patients | 14 | 2 | .492 |
| Myelofibrosis, no. patients | 19 | 6 | 1.000 |
Values represent mean ± SD.